J&J And Sanofi Team Up On Phase III E. Coli Vaccine
Sanofi will pay $175m up front for rights to commercialize J&J’s potential first-in-class vaccine against E. coli. The two companies will share profits.
You may also be interested in...
The French drugmaker is significantly upping its investments in R&D but recent major deals with J&J and Teva show that Sanofi is still open to expanding its external programs as well.
Plus deals involving Advanz/Dimerix, Boehringer Ingelheim/Zeiss Medical Technology, Roche/Ionis, Kriya/Everads and updates from the world of technology transfer.
Clinical work on the US biotech’s drug-Fc conjugate, CD388, has been stopped by partner Janssen amid a broader company shift, but there are several paths forward for Cidara after the asset showed early promise in a Phase IIa trial.